Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF‐ĸB signalling pathway

Camila Leiva‐Castro; Ana Maria Múnera‐Rodríguez; Macarena Martínez‐Bailén; Ana Teresa Carmona; Soledad López‐Enríquez; Francisca Palomares

doi:10.1111/bph.70115

journal article Open Access Jun 18, 2025

Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF‐ĸB signalling pathway

Camila Leiva‐Castro Ana Maria Múnera‐Rodríguez Macarena Martínez‐Bailén Ana Teresa Carmona Soledad López‐Enríquez Francisca Palomares

British Journal of Pharmacology Vol. 182 No. 21 pp. 5157-5172 · Wiley

View at Publisher Save 10.1111/bph.70115

Abstract

Background and PurposeSulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN‐glycoconjugates effects on lipopolysaccharide (LPS)‐induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN‐glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti‐inflammatory and immune‐modulatory properties in DCs from healthy donors under chronic LPS exposure.Experimental ApproachBy leveraging therapeutic strategies, SFN‐glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte‐derived DCs were treated with SFN‐glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS.Key ResultsOur results showed that SFN‐glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF‐κB pathway, without affecting MAPK signalling. SFN‐glycoconjugates induce a tolerogenic immune response, characterized by increased IL‐10 production and enhanced regulatory T‐ and B‐cell proliferation. These effects surpass those of p65 NF‐κB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways.Conclusion and ImplicationsThe integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN‐glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti‐inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.

Topics

No keywords indexed for this article. Browse by subject →

References

50

[1]

10.1111/bph.16176

[2]

10.1111/bph.14112

[3]

10.3390/polym13010088

[4]

10.1016/j.jaci.2021.06.012

[5]

10.1007/978-1-60761-795-2_6

[6]

10.3389/fimmu.2020.00134

[7]

10.3390/antiox11071274

[8]

10.4049/jimmunol.1303259

[9]

10.18632/oncotarget.23208

[10]

10.1016/j.yexcr.2020.112292

[11]

10.1016/j.biomaterials.2021.121303

[12]

10.1111/bph.17441

[13]

10.1016/j.ymthe.2017.01.025

[14]

10.3390/nu15153405

[15]

10.1016/j.jnutbio.2022.109101

[16]

10.1038/ni.1778

[17]

10.3390/antiox13030356

[18]

10.1186/1479-5876-8-4

[19]

10.1016/j.bbadis.2009.12.009

[20]

10.1016/j.imbio.2013.10.013

[21]

10.1080/20013078.2020.1753420

[22]

10.1101/cshperspect.a001651

[23]

10.1021/acsami.5b06541

[24]

10.1016/j.febslet.2006.10.009

[25]

10.1371/journal.pone.0118473

[26]

10.3390/molecules26030752

[27]

10.1039/d2cs00736c

[28]

10.1021/acsomega.0c06294

[29]

10.1080/17425247.2020.1783237

[30]

10.1016/j.biopha.2024.117056

[31]

10.1002/mnfr.201700669

[32]

10.1016/j.carres.2022.108580

[33]

10.1002/mnfr.201900553

[34]

10.1039/c9bm01385g

[35]

10.1021/acs.molpharmaceut.0c00048

[36]

10.1039/d1cc01281a

[37]

10.1021/bm300998c

[38]

10.1038/s41598-019-40114-7

[39]

10.3390/antiox9060521

[40]

10.3389/fncel.2021.787258

[41]

10.3389/fmolb.2021.649395

[42]

10.1016/j.jaci.2016.02.029

[43]

10.1038/s41598-021-83603-4

[44]

10.3389/fimmu.2020.589818

[45]

10.3892/etm.2017.4649

[46]

10.1016/j.exer.2022.108946

[47]

10.1080/13880209.2021.1992450

[48]

10.3390/ijms23041940

[49]

10.1016/j.heliyon.2019.e02951

[50]

10.1038/s41523-022-00402-4

Cited By

4

Monovalent mannose‐glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions

María Elena Angarita‐Planchez, Camila Leiva‐Castro · 2025

British Journal of Pharmacology

Metrics

4

Citations

50

References

Details

Published: Jun 18, 2025
Vol/Issue: 182(21)
Pages: 5157-5172
License: View

Authors

C

Camila Leiva‐Castro

Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Facultad de Medicina Universidad de Sevilla Sevilla Spain

A

Ana Maria Múnera‐Rodríguez

Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Facultad de Medicina Universidad de Sevilla Sevilla Spain

M

Macarena Martínez‐Bailén

Departamento de Química Orgánica, Facultad de Química Universidad de Sevilla Sevilla Spain

A

Ana Teresa Carmona

Departamento de Química Orgánica, Facultad de Química Universidad de Sevilla Sevilla Spain

S

Soledad López‐Enríquez

Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Facultad de Medicina Universidad de Sevilla Sevilla Spain; Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC Sevilla Spain

F

Francisca Palomares

Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Facultad de Medicina Universidad de Sevilla Sevilla Spain; Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC Sevilla Spain

Funding

Universidad de Sevilla Award: 202200000421

MINISTERIO DE CIENCIA E INNOVACIÓN Award: PID2020‐116460RB‐100

Asociación Universitaria Iberoamericana de Postgrado

Cite This Article

Camila Leiva‐Castro, Ana Maria Múnera‐Rodríguez, Macarena Martínez‐Bailén, et al. (2025). Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF‐ĸB signalling pathway. British Journal of Pharmacology, 182(21), 5157-5172. https://doi.org/10.1111/bph.70115

Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF‐ĸB signalling pathway

You May Also Like